强生公司公布的最新一年期临床研究结果显示,其研发的Icotyde™(Icotrokinra)在治疗斑块型银屑病方面展现出持久的皮肤清除效果与良好的安全特性。该每日一次口服疗法在长期用药过程中持续表现出显著疗效,同时维持了可靠的安全性轮廓。
强生公司公布的最新一年期临床研究结果显示,其研发的Icotyde™(Icotrokinra)在治疗斑块型银屑病方面展现出持久的皮肤清除效果与良好的安全特性。该每日一次口服疗法在长期用药过程中持续表现出显著疗效,同时维持了可靠的安全性轮廓。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.